Experimental cancer drug trial halted early after only 17 patients

NCT ID NCT06052852

Terminated Disease control Sponsor: Bolt Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 16, 2026 · Updated 20 times

Summary

This early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers such as breast, kidney, ovarian, head and neck, colorectal, lung, and skin cancer. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
NEXT Oncology

Austin, Texas, 78758, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
NEXT Virginia

Fairfax, Virginia, 22031, United States
Stanford Cancer Center

Palo Alto, California, 94304, United States

Conditions

Explore the condition pages connected to this study.

CLEAR CELL RENAL CELL CARCINOMA COLORECTAL CANCER HEAD AND NECK CANCER MELANOMA NON SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER OVARIAN CANCER TRIPLE NEGATIVE BREAST CANCER